Scientific Notes

Breast cancer remains the most common malignancy in women worldwide, and progress in treatment increasingly depends

Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no

Introduction Microphysiological systems (MPS) are fast becoming a cornerstone of FDA-aligned non-clinical strategy, especially when paired

Introduction Organoid and artificial intelligence approaches are central to the FDA’s roadmap for reducing animal use

Introduction Adipose tissue-breast cancer crosstalk is emerging as a key driver of tumor initiation, progression, and

Introduction Following our articles on how breast cancer organoids and breast‑cancer‑on‑chip platforms expand beyond conventional 2D and